Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HGTV-43
- Development stage
- Unknown
- Lead developer
- Battery Ventures
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HGTV-43 is an investigational gene therapy developed by Enzo Therapeutics for the treatment of HIV-1 infection. It utilizes a proprietary vector (StealthVector HGTV43) to deliver anti-HIV-1 antisense RNA genes into autologous blood stem cells ex vivo. These engineered stem cells are then engrafted back into the patient’s bone marrow, where they produce progeny immune CD4 T cells containing the antisense RNA genes. The circulating engineered immune cells express anti-HIV-1 antisense RNA, which inhibits replication of HIV in these cells and confers resistance to infection. Preclinical studies demonstrated resistance to HIV in human immune cells with inserted antisense genes, and early-phase clinical trials showed successful engraftment and long-term persistence of modified immune cells in patients[1][2][3]. The drug is currently in Phase II clinical development for HIV-1 infections[3].
- Brand names
- StealthVector
- Other names
- StealthVector HGTV43
02
Targets
HIV-1 RNA (HIV-1 RNA genome)
Beyond the preview
Go deeper on HGTV-43.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HGTV-43.